Hostname: page-component-7bb8b95d7b-lvwk9 Total loading time: 0 Render date: 2024-10-02T02:35:25.987Z Has data issue: false hasContentIssue false
  • English
  • Français

Current and emerging drugs treatment for night eating syndrome

Published online by Cambridge University Press:  23 March 2020

M. Martellini ,
M. Barchiesi ,
M.G. Oriani  and
B. Nardi
M. Martellini*
Affiliation:
Polytechnic University of Marche, Clinica di Psichiatria, Ancona, Italy
M. Barchiesi
Affiliation:
Polytechnic University of Marche, Clinica di Psichiatria, Ancona, Italy
M.G. Oriani
Affiliation:
Dipartimento di Salute Mentale Ancona ASUR Marche, Dipartimento di Salute Mentale Ancona ASUR Marche, Ancona, Italy
B. Nardi
Affiliation:
Polytechnic University of Marche, Clinica di Psichiatria, Ancona, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The night eating syndrome (NES) is a categorized in the diagnostic and statistic manual (DSM-5) as an “Other Specified Feeding or Eating Disorder” and it is characterized by a reduced feeding during the day, evening hyperphagia accompagned by frequent nocturnal awakenings associated with conscious episodes of compulsive ingestion of food and abnormal circadian rhythms of food and other neuroendocrine factors. Frequently it is associated with obesity and depressed mood.

Objectives

The purpose of this review is to investigate the state of art concerning the psychopharmacological treatment of NES.

Methods

A Medline enquiry of published articles from 2005 to October 2015 was performed using the following keywords: “NES, pharmacological treatment, SSRI, antidepressants, antipsychotic, sertraline, citalopram, escitalopram, duloxetine, venlafaxine, paroxetine, fluoxetine, fluvoxamine, topiramate”. Reviews, single case studies and RCT were also analyzed.

Results

Only few studies met the selection criteria. A recent 8-week double-blind placebo controlled study, in 34 patients with NES, has confirmed the efficacy of sertraline. Sertraline was associated with significantly greater improvement than placebo in overall symptomatology.

Conclusions

SSRIs should be considered the drug of choice for the treatment of NES not only because of evidence in the literature but also since they display the best pharmacological profiles with fewer adverse events. More evidence of efficacy is shown for some SSRIs such us paroxetine, fluvoxamine and especially sertraline. Topiramate should be reserved for cases resistant to treatment with SSRIs.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW210
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S164 - S165
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.